Company: OCEA
Filing Date: 2025-04-01
Form Type: 8-K
Source: 0001641172-25-002074
Chunk: 0

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-01
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item
5.07 Submission of Matters to a Vote of Security Holders

On
March 28, 2025, we held an annual meeting of stockholders (the “ Meeting”). The Inspector of Elections determined that there
were 59,790,931 represented of the 140,584,743 common shares of the Company at the meeting amounting to 42.530 % of voting shares. At
the Meeting, the Company’s stockholders approved the following proposals (with percentages relating to the number of shares voted
on each matter):

1.
Election of Directors

  For      Against      Abstain      Broker Non-Vote  
 ──────────────────────────────────────────────────────

(1)
Dr. Chirinjeev Kathuria, M. D.

  28,473,831      4,276,790      281,736      26,758,574  

(2)
Elizabeth Ng, M. D.

  30,342,761      2,414,667      274,929      26,758,574  

(3)
Jonathan Kurtis, M. D., Ph. D

  30,625,072      2,125,038      282,247      26,758,574  

(4)
Michael Peterson

  30,520,515      2,210,232      301,610      26,758,574  

2.
Approval of a. Reverse Split of issued and outstanding shares of common stock approval in a range of 1:2 to 1:250.

         For         Against      Abstain  
 ───────────────────────────────────────────
  43,708,050      15,757,223      325,658  

3.
Approval of 2025 Equity Compensation Plan.

         For        Against      Abstain      Broker Non-Vote  
 ───────────────────────────────────────────────────────────────
  28,773,654      4,136,878      121,825           26,758,574  

4.
Ratification of Auditors Berkowitz Pollack & Brandt as our independent registered public accounting firm for the year ending December
31, 2025.

         For        Against      Abstain  
 ──────────────────────────────────────────
  55,487,338      3,329,999      973,594  

5.
Approve a non-binding